Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

An RNA toolbox for cancer immunotherapy.

Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I.

Nat Rev Drug Discov. 2018 Sep 7. doi: 10.1038/nrd.2018.132. [Epub ahead of print] Review.

PMID:
30190565
2.

International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain.

Berraondo P, Aznar MA, Perez-Ruiz E, Rodriguez-Ruiz ME, Castañon E, Perez-Gracia JL, Melero I.

Cancer Immunol Immunother. 2018 Sep 4. doi: 10.1007/s00262-018-2240-y. [Epub ahead of print] No abstract available.

PMID:
30182281
3.

LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC).

Argilés G, Saro J, Segal NH, Melero I, Ros W, Marabelle A, Rodriguez ME, Albanell J, Calvo E, Moreno V, Cleary JM, Eder P, Paz-Ares L, Hurwitz H, Bacac M, Perro M, Bouseida S, Sandoval F, Sabanes Bove D, Sreckovic S, Jamois C, Silva A, Klein C, Umana P, Karanikas V, Tabernero J.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.003. No abstract available.

PMID:
30052786
4.

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.

Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S.

Trends Immunol. 2018 Aug;39(8):644-655. doi: 10.1016/j.it.2018.06.001. Epub 2018 Jul 11. Review.

PMID:
30001871
5.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

6.

Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy.

Etxeberria I, Teijeira A, Montuenga LM, Berraondo P, Melero I.

Cancer Discov. 2018 Jul;8(7):794-796. doi: 10.1158/2159-8290.CD-18-0573.

PMID:
29967073
7.

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Fusco JP, Pita G, Pajares MJ, Andueza MP, Patiño-García A, de-Torres JP, Gurpide A, Zulueta J, Alonso R, Alvarez N, Pio R, Melero I, Sanmamed MF, Rodriguez Ruiz M, Gil-Bazo I, Lopez-Picazo JM, Casanova C, Baz Davila R, Agudo A, Lozano MD, Gonzalez A, Sala N, Ardanaz E, Benitez J, Montuenga L, Gonzalez-Neira A, Perez-Gracia JL.

Cancer Med. 2018 May 15. doi: 10.1002/cam4.1500. [Epub ahead of print]

8.

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.

Teijeira A, Labiano S, Garasa S, Etxeberria I, Santamaría E, Rouzaut A, Enamorado M, Azpilikueta A, Inoges S, Bolaños E, Aznar MA, Sánchez-Paulete AR, Sancho D, Melero I.

Cancer Immunol Res. 2018 Jul;6(7):798-811. doi: 10.1158/2326-6066.CIR-17-0767. Epub 2018 Apr 20.

PMID:
29678874
9.

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.

Martinez-Calle N, Rodriguez-Otero P, Villar S, Mejías L, Melero I, Prosper F, Marinello P, Paiva B, Idoate M, San-Miguel J.

Haematologica. 2018 Jul;103(7):e318-e321. doi: 10.3324/haematol.2017.185777. Epub 2018 Apr 12. No abstract available.

10.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
11.

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.

Berraondo P, Etxeberria I, Ponz-Sarvise M, Melero I.

Clin Cancer Res. 2018 Jun 15;24(12):2716-2718. doi: 10.1158/1078-0432.CCR-18-0381. Epub 2018 Mar 16.

PMID:
29549160
12.

Introducing a New Series: Immunotherapy Facts and Hopes.

Melero I, Sznol M, Tessmer MS, Whiteside TL, Wolchok JD.

Clin Cancer Res. 2018 Apr 15;24(8):1773-1774. doi: 10.1158/1078-0432.CCR-18-0408. Epub 2018 Feb 23. No abstract available.

PMID:
29476022
13.

Radiation effects on antitumor immune responses: current perspectives and challenges.

Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F.

Ther Adv Med Oncol. 2018 Jan 18;10:1758834017742575. doi: 10.1177/1758834017742575. eCollection 2018. Review.

14.

Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

Ochoa MC, Minute L, López A, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, Mayer JA, Wirtz P, Melero I, Berraondo P.

Oncoimmunology. 2017 Nov 13;7(2):e1393597. doi: 10.1080/2162402X.2017.1393597. eCollection 2018.

PMID:
29308327
15.

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Azpilikueta A, Bolaños E, Lang V, Labiano S, Aznar MA, Etxeberria I, Teijeira A, Rodriguez-Ruiz ME, Perez-Gracia JL, Jure-Kunkel M, Zapata JM, Rodriguez MS, Melero I.

Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017.

16.

Cancer immunotherapy full speed ahead.

Melero I, Navarro B, Teijeira A, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii1-xii2. doi: 10.1093/annonc/mdx739. No abstract available.

PMID:
29253117
17.

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.

Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii74. doi: 10.1093/annonc/mdx727. No abstract available.

PMID:
29253116
18.

Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes.

Iñarrairaegui M, Melero I, Sangro B.

Clin Cancer Res. 2018 Apr 1;24(7):1518-1524. doi: 10.1158/1078-0432.CCR-17-0289. Epub 2017 Nov 14. Review.

PMID:
29138342
19.

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.

Aznar MA, Labiano S, Diaz-Lagares A, Molina C, Garasa S, Azpilikueta A, Etxeberria I, Sanchez-Paulete AR, Korman AJ, Esteller M, Sandoval J, Melero I.

Cancer Immunol Res. 2018 Jan;6(1):69-78. doi: 10.1158/2326-6066.CIR-17-0159. Epub 2017 Nov 13.

PMID:
29133290
20.

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.

Chester C, Sanmamed MF, Wang J, Melero I.

Blood. 2018 Jan 4;131(1):49-57. doi: 10.1182/blood-2017-06-741041. Epub 2017 Nov 8. Review.

PMID:
29118009
21.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

PMID:
29025772
22.

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.

Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii44-xii55. doi: 10.1093/annonc/mdx237. Erratum in: Ann Oncol. 2017 Dec 1;28(suppl_12):xii74.

PMID:
28945841
23.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

24.

Interleukin-8 in cancer pathogenesis, treatment and follow-up.

Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I.

Cancer Treat Rev. 2017 Nov;60:24-31. doi: 10.1016/j.ctrv.2017.08.004. Epub 2017 Aug 31. Review.

PMID:
28866366
25.

Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies.

Rodriguez-Ruiz ME, Rodriguez I, Barbes B, Mayorga L, Sanchez-Paulete AR, Ponz-Sarvise M, Pérez-Gracia JL, Melero I.

Brachytherapy. 2017 Nov - Dec;16(6):1246-1251. doi: 10.1016/j.brachy.2017.06.012. Epub 2017 Aug 21.

PMID:
28838649
26.

Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.

Pérez-Ruiz E, Etxeberria I, Rodriguez-Ruiz ME, Melero I.

Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.

27.

Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells.

Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Martínez-Cano S, Mejías-Pérez E, Esteban M, Melero I, Hidalgo A, Sancho D.

Nat Commun. 2017 Jul 17;8:16073. doi: 10.1038/ncomms16073.

28.

Cellular immunotherapies for cancer.

Berraondo P, Labiano S, Minute L, Etxeberria I, Vasquez M, Sanchez-Arraez A, Teijeira A, Melero I.

Oncoimmunology. 2017 May 2;6(5):e1306619. doi: 10.1080/2162402X.2017.1306619. eCollection 2017. Review.

29.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

30.

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.

Labiano S, Meléndez-Rodríguez F, Palazón A, Teijeira Á, Garasa S, Etxeberria I, Aznar MÁ, Sánchez-Paulete AR, Azpilikueta A, Bolaños E, Molina C, de la Fuente H, Maiso P, Sánchez-Madrid F, de Landázuri MO, Aragonés J, Melero I.

Oncoimmunology. 2017 Jan 19;6(4):e1283468. doi: 10.1080/2162402X.2017.1283468. eCollection 2017.

31.

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I.

Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.

PMID:
28434648
32.

Targeting NK-cell checkpoints for cancer immunotherapy.

Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I.

Curr Opin Immunol. 2017 Apr;45:73-81. doi: 10.1016/j.coi.2017.01.003. Epub 2017 Feb 23. Review.

PMID:
28236750
33.

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.

Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inogés S, Melero I, Berraondo P.

Immunol Cell Biol. 2017 Apr;95(4):347-355. doi: 10.1038/icb.2017.6. Epub 2017 Feb 21. Review.

PMID:
28138156
34.

T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions.

Teijeira A, Hunter MC, Russo E, Proulx ST, Frei T, Debes GF, Coles M, Melero I, Detmar M, Rouzaut A, Halin C.

Cell Rep. 2017 Jan 24;18(4):857-865. doi: 10.1016/j.celrep.2016.12.078.

35.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

36.

Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium.

Rodriguez-Ruiz ME, Garasa S, Rodriguez I, Solorzano JL, Barbes B, Yanguas A, Teijeira A, Etxeberria I, Aristu JJ, Halin C, Melero I, Rouzaut A.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):389-400. doi: 10.1016/j.ijrobp.2016.10.043. Epub 2016 Nov 7.

PMID:
28068246
37.

Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.

Aznar MA, Tinari N, Rullán AJ, Sánchez-Paulete AR, Rodriguez-Ruiz ME, Melero I.

J Immunol. 2017 Jan 1;198(1):31-39. Review.

38.

Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy.

Melero I, Berraondo P, Rodríguez-Ruiz ME, Pérez-Gracia JL.

Cancer Discov. 2016 Dec;6(12):1312-1314.

39.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R.

Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18.

40.

Innate immune mediators in cancer: between defense and resistance.

Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R.

Immunol Rev. 2016 Nov;274(1):290-306. doi: 10.1111/imr.12464. Review.

PMID:
27782320
41.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I.

Cancer Res. 2016 Oct 15;76(20):5994-6005. Epub 2016 Aug 22.

42.

Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing.

Teijeira A, Etxeberria I, Ponz-Sarvise M, Melero I.

Clin Cancer Res. 2016 Sep 1;22(17):4277-9. doi: 10.1158/1078-0432.CCR-16-1072. Epub 2016 Jun 21.

43.

Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.

Berraondo P, Ochoa MC, Rodriguez-Ruiz ME, Minute L, Lasarte JJ, Melero I.

Cancer Res. 2016 May 15;76(10):2863-7. doi: 10.1158/0008-5472.CAN-15-3279. Epub 2016 May 2.

44.

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA.

Drugs. 2016 Jun;76(9):925-45. doi: 10.1007/s40265-016-0588-x. Review.

PMID:
27229745
45.

Emerging Opportunities and Challenges in Cancer Immunotherapy.

Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I.

Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049. Review.

46.

Cancer Immunosurveillance Caught in the Act.

Berraondo P, Teijeira A, Melero I.

Immunity. 2016 Mar 15;44(3):525-526. doi: 10.1016/j.immuni.2016.03.004.

47.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

48.

Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

Weigelin B, Bolaños E, Rodriguez-Ruiz ME, Martinez-Forero I, Friedl P, Melero I.

Cancer Immunol Immunother. 2016 May;65(5):493-7. doi: 10.1007/s00262-016-1818-5. Epub 2016 Mar 12.

PMID:
26970765
49.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.

50.

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.

Labiano S, Palazón A, Bolaños E, Azpilikueta A, Sánchez-Paulete AR, Morales-Kastresana A, Quetglas JI, Perez-Gracia JL, Gúrpide A, Rodriguez-Ruiz M, Aznar MA, Jure-Kunkel M, Berraondo P, Melero I.

Oncoimmunology. 2015 Jun 24;5(1):e1062967. eCollection 2016.

Supplemental Content

Loading ...
Support Center